Insider trade

Officer received an award of 27K JNJ derivative securities

Traded Feb 9, 2026 · Filed Feb 12, 2026

Johnson & JohnsonJNJ

27K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 9, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 12, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000200406-26-000030
Filed / recorded

Feb 12, 2026, 1:45 AM UTC

Added to OQRO

Oct 2, 2026, 3:52 AM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

JOHNSON & JOHNSON

Issuer CIK

200406

Ticker

JNJ

Reporting person

Jennifer L Taubert

Relationship

Officer

Officer title

EVP, WWC. Innovative Medicine

Security

Performance Share Units

Table

Derivative (Table II)

Transaction date

Feb 9, 2026

Transaction code

A

Shares / units

27,412

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

27,412

Ownership form

Direct

Amendment

No

Footnotes from the filing

Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting.
The number of PSUs reflects the target number of PSUs originally granted on February 13, 2023, adjusted to reflect achievement relative to the performance conditions set forth in the award agreement, as certified on February 9, 2026.